An Enriched Nabiximols Trial Tested Sustained Response Among Initial Responders
A 2011 review described a nabiximols trial that randomized patients only after identifying an initial response to treatment. That design can address sustained benefit in responders, while answering a narrower question than benefit in every patient starting treatment.
The initial phase selected the later population
In the described trial, patients with resistant multiple-sclerosis spasticity first received single-blind treatment. Those meeting the initial improvement criterion could enter the randomized comparison. The later result therefore applies to a selected group, not automatically to everyone assessed initially.
A symptom rating was the primary outcome
The review emphasized patient-recorded numerical spasticity scores. A meaningful symptom response remains different from reversal of the underlying disease, improvement on every objective function or preserved driving ability. Each requires its own evidence.
Other designs supplied different comparisons
The review also described conventional trials and a per-protocol analysis. Results from these approaches need their analysis population and comparator attached. A favorable pooled narrative should not conceal who was included in each estimate or who discontinued treatment.
Interpreting the evidence
This historical review is useful for interpreting responder-enriched designs. It does not establish a universal likelihood of benefit, absence of tolerance or a modern personal treatment recommendation. Product identity and the selected trial population remain central.
Related reading: interpreting cannabis tolerance claims.
Research reference
Vermersch P (2011). Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Expert review of neurotherapeutics. doi:10.1586/ern.11.27.
This analysis draws on the supplied review abstract.
